Top 5 Biotech Startup Investors in Isle of Man (October 2026)

We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.

Investment focus

Industry: Biotechnology, Health Care, Medical
Stage:Series B, Series C, Series A
Geography: United States, United Kingdom, China

Investor stats

Total investments: 225
Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
Lead/follow: 28% lead, 72% follow
Last fund: Likely still investing — raised $900M in 2024

Portfolio highlights

Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.

Show all investments...

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Investment focus

Industry: Biotechnology, Food and Beverage, Food Processing
Stage:Series A, Seed
Geography: United States, United Kingdom, Israel

Investor stats

Total investments: 35
Round size: Seed $894k–$20M; Series A $3M–$47M
Lead/follow: 46% lead, 54% follow

Portfolio highlights

Callers AI — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.

Show all investments...

We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Investment focus

Industry: Biotechnology, Pharmaceutical, Health Care
Stage:Venture - Series Unknown, Series A, Seed
Geography: United States, Hong Kong, Isle of Man

Investor stats

Total investments: 17
Round size: Series A $3M–$19M; Venture - Series Unknown $1.5M–$10M
Lead/follow: 47% lead, 53% follow

Portfolio highlights

LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
Morphoceuticals — Reprogramming the Software of Life: Understanding the bioelectric network that controls tissue repair and organ regeneration
MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.

Show all investments...

Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.

Investment focus

Industry: Biotechnology, Pharmaceutical, Health Care
Stage:Series A, Post-IPO Equity, Seed
Geography: United States, Isle of Man

Investor stats

Total investments: 10
Round size: Series A $3M–$19M; Post-IPO Equity $15M–$80M
Lead/follow: 50% lead, 50% follow

Portfolio highlights

Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Serina Therapeutics — Serina Therapeutics is a biotech company focused on polymer technology to improve how small molecule therapeutics behave in the body
Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

Show all investments...